Gene for coding Marburg virus glycoprotein, related mRNA molecule and application thereof

Through the Marburg virus glycoprotein gene optimized by human-preferential codon, DNA and mRNA vaccines were constructed and their immunogenicity was evaluated in mice, which solved the problem of insufficient translation quality and safety of existing vaccines, and achieved the Strong immune response and preventive effects.

CN119061027APending Publication Date: 2024-12-03FOURTH MILITARY MEDICAL UNIVERSITY
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411228994.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing Marlborough virus vaccine has not been approved yet, and the translation quality and safety of unoptimized antigen genes encoding pathogens need to be improved, resulting in poor effectiveness of nucleic acid vaccines in preventing Marlborough hemorrhagic fever.

Method used

The Marburg virus glycoprotein gene optimized by human preference codons was provided for the construction of DNA and mRNA vaccines, their immunogenicity was evaluated by intramuscular injection in BALB/c mice, and by pVAX1 vector and pGEM- UTR-GPMARV vector realizes gene and mRNA expression.

Benefits of technology

Successfully induced a strong humoral immune response and T cell response, enhancing the immune response-related pathways, demonstrating the potential of these vaccines in preventing Marburg hemorrhagic fever.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061027A_ABST
    Figure CN119061027A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of nucleic acid vaccines, and particularly relates to a coding gene of Marburg virus glycoprotein, a related mRNA (messenger Ribonucleic Acid) molecule and application thereof. The nucleotide sequence of the gene is as shown in SEQ ID NO.1. A DNA vaccine for preventing Marburg virus is prepared from a vector containing the gene. A transcription template DNA (deoxyribonucleic acid) sequence of the mRNA molecule is shown as SEQ ID NO.2, all uridine in the mRNA molecule is replaced by N1-methyl-pseudouridine-5 '-triphosphate, and the mRNA vaccine for preventing the Marburg virus is prepared by utilizing the mRNA molecule. When the DNA vaccine and the mRNA vaccine are used for immunizing animals (BALB / c mice) for immunological evaluation, it is proved that candidate nucleic acid vaccines can induce antigen-specific body fluid and cellular immune response of immunized mice, and the potential of novel MARV nucleic acid vaccines in preventing Marburg virus diseases is proved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of nucleic acid vaccines, and in particular relates to a gene encoding Marburg virus glycoprotein, related mRNA molecules and uses thereof. Background Art

[0002] Marburg virus (MARV) is a zoonotic virus that infects humans and non-human primates (NHPs) and causes the fatal Marburg hemorrhagic fever (MHF). The virus is a single-stranded, unsegmented, negative-strand RNA virus belonging to the family Filoviridae. Discovered by German scientists in 1967, it has so far caused 16 sporadic outbreaks in Africa, Europe, and elsewhere, with an average mortality rate of 88%. Among them, the mortality rate of the 2005 Angola outbreak was as high as 90%. Recently, cases of MARV infection have been reported in many parts of the world, once again sounding the alarm for global epidemic prevention and control. Considering human-to-human transmission and high mortality, the World Health Organization has listed MARV as a biosafety level 4 pathogen and identified it as a priority pathogen for urgent vaccine development. However, there is currently no approved MHF vaccine or antiviral treatment. Therefore, it is of great significance to develop a simple and effective candidate vaccine for the prevention and treatment of MARV infection.

[0003] In recent years, nucleic acid vaccines have become a research hotspot due to their significant advantages such as simple design and preparation process, few adverse reactions, convenient storage and transportation, and ability to simulate natural infection to induce immune protection response. DNA vaccines can express and produce corresponding protein antigens without taking up antigen presenting cells (APCs) and stimulate the immune response of T cells and B cells. mRNA vaccines only target delivery to the cytoplasm, eliminating the risk of genome integration and acting independently of cell division, which is its unique advantage. However, the translation quality and safety of unoptimized genes encoding pathogen antigens need to be further improved. Summary of the invention

[0004] In view of the above technical problems, the present invention provides a gene encoding MARV GP and two candidate nucleic acid vaccines prepared using the gene. The immunogenicity of the MARV candidate nucleic acid vaccine in BALB / c mice was evaluated by intramuscular injection of each candidate vaccine.

[0005] The specific technical solutions provided by the present invention are as follows:

[0006] In a first aspect, the present invention provides a gene encoding Marburg virus glycoprotein, the nucleotide sequence of which is shown in SEQ ID NO.1. The present invention performs human-preferred codon optimization on the basis of the MARV GP gene, and its codons have the characteristics of human preference. Compared with the original gene, it has the advantages of improving protein translation quality and strong safety.

[0007] The second aspect of the present invention provides a vector containing the gene.

[0008] In a specific embodiment of the present invention, the vector is a pVAX1 vector, and the vector containing the gene is constructed by inserting the gene shown in SEQ ID NO.1 into the BamH I and Xho I sites of the pVAX1 vector.

[0009] The third aspect of the present invention provides use of the vector in preparing a DNA vaccine for preventing Marburg virus.

[0010] In a fourth aspect, the present invention provides a DNA vaccine for preventing Marburg virus, wherein the DNA vaccine contains the above-mentioned vector.

[0011] In a fifth aspect, the present invention provides an mRNA molecule expressing Marburg virus glycoprotein, wherein the transcription template DNA of the mRNA molecule comprises the gene encoding the Marburg virus glycoprotein, and the transcription template DNA sequence is shown in SEQ ID NO.2;

[0012] The mRNA molecule comprises a modified nucleoside, which is a pseudouridine.

[0013] In a specific embodiment of the present invention, the transcription template DNA of the mRNA molecule is sequentially connected by the 5'UTR region, positions 1-2145 of the gene fragment shown in SEQ ID NO.1, the 3'UTR region and polyadenylic acid (PolyA) to form the fragment shown in SEQ ID NO.2.

[0014] Preferably, the 5′UTR and 3′UTR sequences are derived from Homo sapiens hemoglobin subunit β, the 5′UTR sequence includes a regulatory sequence and the 5′UTR sequence of β-globin, and the 3′UTR sequence consists of the tandem sequence of two fragments of the 3′UTR of β-globin.

[0015] Preferably, the PolyA tail is 120 nt in length.

[0016] Preferably, the pseudouridine is N1-methyl-pseudouridine-5′-triphosphate, and all uridines in the mRNA molecule are replaced by N1-methyl-pseudouridine-5′-triphosphate.

[0017] In a sixth aspect, the present invention provides use of the mRNA molecule expressing Marburg virus glycoprotein in the preparation of an mRNA vaccine for preventing Marburg virus.

[0018] In a seventh aspect, the present invention provides an mRNA vaccine for preventing Marburg virus, comprising the mRNA molecule expressing the Marburg virus glycoprotein.

[0019] Compared with the prior art, the present invention has the following beneficial effects:

[0020] The present invention successfully constructed GP-based MARV DNA and mRNA candidate vaccines, proving that both vaccines can induce strong humoral immune responses, enhance T cell responses, and activate immune response-related pathways. Our research provides new ideas for MARV nucleic acid vaccines and further confirms the potential of nucleic acid vaccines in the prevention and control of MHF in the future. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 MARV GP prokaryotic expression vector pET28a-GP MARV Vector map (A) and plasmid identification by 1% agarose gel electrophoresis (B), lane 1 is pET28a-GP MARV The fragment size of the product digested by BamH I and Xho I is 2.1k+5.3k.

[0022] Figure 2 For the construction and identification of candidate vaccines. A is pVAX-GP MARV Vector and pGEM-UTR-GP MARV The structure of the vector and its restriction endonuclease sites. B is the plasmid identified by 1% agarose gel electrophoresis, and lane 1 is pVAX-GP MARV The product of the vector digested by BamH I and Xho I, the fragment size is 2.1k+2.9k; Lane 2 is pGEM-UTR-GP MARV The product of the vector digested by BamH I and Xho I, the fragment size is 2.1k+4.5k. C is qRT-PCR detection of MARV GP mRNA expression in HEK293T cells transfected with MARV GP DNA or mRNA (1mg / mL), with β-actin as an internal reference. D is the expression of MARV GP protein in transfected HEK293T cells detected by western blot 48h after transfection. E is immunofluorescence staining of GP protein in transfected HEK293T cells 24h after transfection (40×).

[0023] Figure 3 Figure 1 is the evaluation of the immunization regimen and humoral immune response. A is the time points of immunization, serum sample collection and related experiments. B is the evaluation of MARV-specific IgG antibody titers by ELISA after each immunization (n=6). The red dotted line indicates the limit of detection (LOD). C is the detection of neutralizing antibody titers after each booster immunization.

[0024] Figure 4 Comparison of nucleotide sequence similarity between MARV GP and EBOV GP.

[0025] Figure 5 The ELISpot method is used to detect the levels of IFN-γ and IL-4 secreted by mouse spleen cells after booster immunization. A is a representative picture of IFN-γ and IL-4 spot forming units (SFCs) detected by ELISpot after booster immunization under the stimulation of MARVGP peptide. B is a comparison of IFN-γ and IL-4 secretion levels between mice receiving DNA candidate vaccines and mice receiving mRNA candidate vaccines under the stimulation of peptide pool after booster immunization (n=6). C is a heat map of IFN-γ and IL-4 SFCs stimulated by MARV GP single peptide after booster immunization (n=6). D is a representative picture of IFN-γ and IL-4 SFCs produced by mouse spleen cells stimulated by peptide pool after long-acting booster immunization. E is a comparison of IFN-γ and IL-4 secretion levels of mice under the stimulation of 9-peptide, 15-peptide and 16 / 18 / 20-peptide pools after long-acting immunization (n=6). F is the heat map of SFCs producing IFN-γ and IL-4 stimulated by 9-peptide, 16-peptide, 18-peptide and 20-peptide (n=6).

[0026] Figure 6 CD4 + and CD8 + The expression of cytokines in T cells and the proportion of TEM cells. A shows the expression of cytokines in T cells and the proportion of TEM cells. + and CD8 + The gating strategy of T cells is also used for the detection of IL-2 and IL-4. B is the CD4+ T cells that secrete IL-2, IL-4 and IFN-γ after booster immunization. + and CD8 + T cell percentage (n=6). C is CD4 + and CD8 + The secretion level of cytokines in T cells. D is CD4 + The gating strategy of Tem in T cells has also been used to detect CD8 + Tem cells. E is the CD4 Tem cells of the two vaccine candidate groups after the first booster immunization under the stimulation of MARV GP specific peptide pool. + and CD8 + F is the percentage of Tem cells in the two candidate vaccine groups after long-term booster immunization. + and CD8 + The proportion of TEM cells.

[0027] Figure 7This is a safety assessment of the candidate vaccine. A is a H&E staining of the main organs after long-term immunization. B is an evaluation of animal behavior using an automatic analysis system, and a representative heat map of the three groups is shown here. C is a comparison of the activity time, activity distance, diet, grooming, and climbing of the three groups of mice. DETAILED DESCRIPTION

[0028] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.

[0029] Example 1: Encoding gene design and candidate vaccine construction

[0030] 1. Test methods

[0031] 1. Construction and identification of recombinant plasmids

[0032] (1) Construction of DNA vaccine vector

[0033] DNA vaccine candidate vector pVAX-GP MARV It is based on the codon-optimized MARV GP gene sequence and added with 3×Flag tags to obtain the gene fragment shown in SEQ ID NO.1, which is inserted into the Kan-resistant pVAX1 vector through the BamH I and Xho I sites and constructed by Sangon Biotech (Shanghai) Co., Ltd.

[0034] SEQ ID NO.1:

[0035]

[0036] (2) Construction of mRNA vaccine vector

[0037] The 5′UTR region, positions 1-2145 of the gene fragment shown in SEQ ID NO.1, the 3′UTR region and the polyadenylic acid (PolyA) tail were connected in order to form the gene fragment shown in SEQ ID NO.2, and the gene fragment was inserted between the BamH I and Xho I sites of the pGEM vector (Promega; P2411) to construct an in vitro expression vector - pGEM-UTR-GP MARV Plasmids were purified using a plasmid extraction kit (TIANGEN, Beijing), and the accuracy of the plasmids was confirmed by agarose gel electrophoresis and Sanger sequencing.

[0038] SEQ ID NO.2:

[0039]

[0040] pGEM-UTR-GP was transcribed in vitro MARV The vector is further capped to obtain the final mRNA molecule. The specific operation is as follows:

[0041] 1) Linearization of in vitro transcription plasmid

[0042] Prepare the reaction system according to Table 1, slowly pipette and mix, centrifuge briefly, incubate at 37°C for 60 min in a PCR instrument, and then incubate at 65°C for 20 min for heat inactivation. After terminating the reaction, take a portion and run it through 1% agarose gel electrophoresis to compare whether the sequence size is correct. Then use a DNA purification kit to purify and recover the enzyme digestion product to obtain an in vitro transcription linearized template, quantify the DNA template, and store it at -20°C for later use.

[0043] Table 1 In vitro transcription plasmid linearization reaction system

[0044] Components Mass / Volume <![CDATA[pGEM-UTR-GP MARV ]]> 1 μg 10×CutSmart buffer 5μL XB 1μL Nuclease-Free Water To 50μL

[0045] 2) In vitro transcription

[0046] Prepare 20 μL T7 RNA polymerase transcription reaction system and follow the product manual to replace uridine-5′-triphosphate with N1-methyl-pseudouridine-5′-triphosphate (m1ΨTP) to produce mRNA in vitro through T7 RNA polymerase-mediated transcription. Set up the following 20 μL in vitro transcription reaction system on ice:

[0047] Table 2 In vitro transcription reaction system

[0048] Components Mass / Volume 10×Transcription Buffer 2μL ATP / GTP / CTP / m1ΨTP Mix Each 1.5 μL each Template DNA 5μL Enzyme Mix 1μL Nuclease-Free Water To 20μL

[0049] Gently mix all components, centrifuge briefly, collect and incubate in a PCR instrument at 37℃ for 3h. Then add 1μL of DNase I to the reaction system and incubate at 37℃ for 15min to digest the DNA template. Transfer 20μL of in vitro transcription product to a 1.5mL centrifuge tube, add 30μL of 7.5M LiCl and 30μL of RNase Free Water respectively; after mixing, place at -20℃ for at least 30min. Then centrifuge at 12000rpm for 15min, remove the supernatant and collect the precipitate. Wash three times with pre-cooled 70% ethanol, and detect the RNA concentration after re-dissolving with RNase Free Water.

[0050] 3) mRNA capping and purification

[0051] Dilute 25 μg RNA to 33.5 μL with RNase-free water, heat at 65°C for 5 min, place on ice for 5 min, and add the following components in sequence to establish a 50 μL capping reaction system:

[0052] Table 3 Capping reaction system

[0053] Components Mass / Volume Denatured RNA 33.5μL 10x Capping Reaction Buffer 5μL GTP(10mM) 5μL SAM(20mM) 1.25μL Recombinant RNase Inhibitor(40U / μL) 1.25μL mRNA Cap 2′-O-Methyltransferase(100U / μL) 2μL Vaccinia Capping Enzyme(10U / μL) 2μL

[0054] The capped RNA was further purified, quantified, and stored before use. The dsRNA residues were determined using the Novo Fast dsRNA ELISA Kit (Novoprotein, Suzhou, China) to confirm the effectiveness of the mRNA vaccine.

[0055] 2. Transfection of HEK293T cells

[0056] pVAX-GP was transfected with Lipofectamine 3000 (Invitrogen, USA). MARV and mRNA, both at 48 h.

[0057] 3. RNA Isolation and Real-time Fluorescence Quantitative PCR

[0058] Total RNA was extracted from transfected cells using the RNAprep FastPure Kit (Qingdao, Beijing, China). 2×Onestep SYBR Master Mix (Vazyme) was used for cDNA preparation and qRT-PCR. The primers used in this study (Table 4) were synthesized by Qingke Biotechnology Co., Ltd.

[0059] Table 4 Primer sequences

[0060] Primers Sequence (5′-3′) Sequence number MARV-F gggg tgcctctc 3 MARV-R atgtcttccctg cccc t 4 Actin-F atcaagatgctcctgag 5 Actin-R ctgctg tgctcacatctg 6

[0061] 4. Immunoblotting analysis of transfected cells

[0062] The transfected cells were collected with RIPA lysis buffer (Beyotime) and then centrifuged at 4°C, 12000 rpm. The supernatant was added with 5×SDS buffer, boiled for 5 minutes, and then subjected to 10% SDS-PAGE electrophoresis (YaZyme, Shanghai, China). Rabbit anti-Flag antibody (Proteintech) was used to detect antigenic protein.

[0063] 5. Immunofluorescence analysis

[0064] Cells were cultured and transfected in 15 mm glass-bottomed culture dishes. Transfected cells were washed with cold phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde, perforated and blocked with 1% Triton X100 (Beyotime) and goat serum (Solarbio) for 10 min, respectively. Rabbit anti-Flag antibody (Proteintech) and 488-labeled goat anti-rabbit antibody (Proteintech) were used as the first and second antibodies. Cell nuclei were stained with DAPI (Solarbio). Finally, images were obtained using a confocal microscope (FV3000, Olympus, Japan).

[0065] 6. Prokaryotic expression of MARV GP and protein purification

[0066] To obtain MARV GP protein, we constructed pET28a-GP MARV Contains a 6×His tag ( Figure 1 A) When the bacterial culture is at OD 600 When the pH was 0.5-0.6, 0.8 mM isopropyl β-D1-thiogalactoside (IPTG) was added and cultured at 28°C and 160 rpm for 6 h. The GP protein was purified using the His-tag protein purification kit (Beyotime). Figure 1 B).

[0067] 2. Test results

[0068] 1. Construction and identification of candidate vaccines

[0069] Based on the MARV GP gene sequence, the DNA vaccine pVAX-GP was successfully constructed MARV and mRNA vaccine vector pGEM-UTR-GP MARV ( Figure 2 A). They all contain a 3×Flag tag for easy verification in downstream experiments. 5′UTR and 3′UTR were introduced for in vitro transcription, and polyA tail was introduced to improve the stability of mRNA. We inserted the GP gene into the pGEM-UTR plasmid (stored in our laboratory) using double restriction enzymes of BamH I and Xho I. The size of the vector was determined by agarose gel electrophoresis ( Figure 2 B).

[0070] After in vitro transcription and purification of mRNA, we used pVAX-GP MARVHEK293T cells were transfected with vectors and mRNA, and PBS was used as a negative control. qRT-PCR, western blotting, and immunofluorescence were used to verify the transfection efficiency. Both DNA and mRNA of GP were successfully expressed in cells. The mRNA expression level of GP in the mRNA group was significantly higher than that in the DNA group (p<0.001)( Figure 2 C). GP protein was successfully expressed in both groups ( Figure 2 D). Fluorescence images show that GP protein is mainly expressed in the cytoplasm ( Figure 2 E).

[0071] Example 2: Candidate vaccine performance testing

[0072] 1. Test methods

[0073] 1. Immunization plan

[0074] Female BALB / c mice (6-8 weeks) were obtained from the Experimental Animal Center of the Fourth Military Medical University. MARV Or mRNA candidate vaccines were administered into the gastrocnemius muscle at weeks 0, 4, and 24. DNA candidate vaccines contained 30 μg DNA, and mRNA vaccines contained 10 μg mRNA and the corresponding volume of in vivo mRNA transfection reagent (Polyplus). Serum samples were collected two weeks after each immunization.

[0075] 2. Enzyme-linked immunosorbent assay (ELISA)

[0076] The purified MARV GP protein was diluted (final concentration 10 mg / mL) and coated on ELISA plates (Costar) at 100 μL / well at 4°C overnight. The next morning, the plates were washed with PBST and blocked with 1% BSA at 37°C for 1 hour. Then, mouse serum was serially diluted from 1:100 to 1:500,000, 100 μL was added, and left at 37°C for 1 hour. After washing with PBST five times, HRP-conjugated goat anti-mouse IgG (CST) was added and incubated at 37°C for 30 minutes. Then, the plates were washed six times with PBST and 100 μL of TMB substrate (Solarbio) was added. Finally, the ELISA stop solution was added and the absorbance was measured at 450 nm.

[0077] 3. Serum neutralization test

[0078] Vero E6 cells were plated in a 96-well plate. Mouse serum was diluted in a two-fold gradient from 1:10 to 1:160 and mixed with 100-fold TCID 50 rVSV-ΔGP EBOVPseudovirus (published in Liu Y, Sun B, Pan J, Feng Y, Ye W, Xu J, Lan M, Sun H, Zhang X, Sun Y, Yang S, Shi J, Zhang F, Cheng L, Jiang D, Yang K. Construction and evaluation of DNA vaccine encoding Ebola virus glycoprotein fused with lysosome-associated membrane protein. Antiviral Res. 2021 Sep; 193: 105141. doi: 10.1016 / j.antiviral.2021.105141. Epub 2021 Jul 16. PMID: 34274417.) was mixed, incubated at 37 ° C for 1 hour, and then the mixture was added to the prepared Vero E6 cells. After culturing for 2 hours, the supernatant was replaced with fresh culture medium. After incubation for 36 hours, the cell infection was observed, and the 50% protective dose (PD 50 ), and the neutralization titer was calculated using Karber's method.

[0079] 4. Synthesis and preparation of peptides

[0080] The peptides used in this study include 15 types of 9-peptides, 4 groups of 15-peptides and 1 group of 16 / 18 / 20-peptides. All peptides were synthesized by Shanghai Chupeptide Biotechnology Co., Ltd.

[0081] 5. Enzyme-linked immunospot assay (ELISpot)

[0082] Mouse IFN-γ and IL-4 ELISpot kits (BD Biosciences) were used to evaluate the cellular immune response of mice after each boost. Briefly, plates were coated with capture antibodies diluted in sterile PBS at 4°C overnight.

[0083] The next morning, the plates were removed, washed with RPMI 1640 medium containing 10% fetal bovine serum and blocked for 2 h. During this period, spleen cell suspensions of immunized mice were prepared and counted. In addition, the peptides were diluted to a final concentration of 30 μg / mL with RPMI 1640 medium containing 10% fetal bovine serum. Splenocytes (1×10 6Cells / well) were added to the plate and incubated at 37°C for 24h. Wells without peptide addition were used as negative controls, and concanavalin A (2μg / mL, Sigma) was used as positive controls. After incubation, the plate was washed twice with ddH2O and 4 times with PBST, and then incubated with biotin-labeled secondary antibodies for 2h at room temperature. After washing 4 times with PBST, it was incubated with streptavidin-HRP at room temperature for 1 hour. Finally, the color reaction was performed using the HRP 3-amino 9-ethylcarbazole peroxidase substrate kit (Solarbio). The spots were counted and analyzed using an ELISpot plate reader (CTL).

[0084] 6. Flow cytometry

[0085] For cell surface antigen staining, cells were stimulated with 15 / 16 / 18 / 20 mixed peptides (2 μg / mL each). For intracellular cytokine staining, splenocytes were stimulated with cell stimulator (Invitrogen), both for 4 hours at 37°C. Cell fixation and permeabilization solution (BD) was used for fixation and permeabilization. After stimulation, cells were washed with wash buffer and incubated with the following antibodies: CD3-APC-Cyanine7, CD4 / CD8-FITC, CD44-PE, and CD62L-APC for cell surface staining; CD3-FITC, CD4-PE, CD8-Pacific Blue, IL-2 / IL-4 / IFN-γ-APC for intracellular staining. All antibodies were purchased from Biolegend.

[0086] 7. Transcriptome analysis

[0087] Mouse spleen cells were collected, stimulated with peptides at 37°C for 24 h, and then resuspended with TRIzol reagent (Vazyme) and stored at −80°C awaiting sequencing. Transcriptome sequencing was performed by Wuhan Kangce Biotechnology Co., Ltd.

[0088] 8. Animal behavior analysis

[0089] After long-term immunization, the mice were placed in the VB-AIH multi-channel automatic behavior analysis system (Vanbi) for 24 h to record and analyze the animal's behavior, including activity time and distance, eating habits, grooming, and climbing-related data.

[0090] 9. Hematoxylin and eosin (H&E) staining

[0091] After long-term immunization, the main organs of the mice were collected and stained with hematoxylin and eosin (H&E). The sections were observed using an Olympus VS200 microscope.

[0092] 2. Test results

[0093] 1. DNA vaccine candidates show advantages in humoral immunity

[0094] Immunization schedule Figure 3 As shown in A. Mice were randomly divided into 3 groups (14 mice in each group) and injected with pVAX-GP, mRNA or PBS (negative control) at 0, 4 and 24 weeks, respectively. Serum samples were collected two weeks after each injection. ELISA was used to detect MARV-specific IgG antibodies in serum. Figure 3 As shown in B, both candidate vaccines induced humoral immunity in mice, and the specific antibody titers were significantly increased after booster immunization and long-acting booster immunization. It is worth noting that the DNA candidate vaccine group induced more specific antibodies both immediately and after booster immunization.

[0095] Evaluation of neutralizing antibody production is crucial in vaccine research because it largely reflects the effectiveness of candidate vaccines. Considering the conservative relationship between MARV and EBOV GP ( Figure 4 ), we used rVSV-ΔGP EBOV Used for serum neutralization test. Figure 3 As shown in C, compared with the control group, both DNA and mRNA candidate vaccines induced the production of neutralizing antibodies, with average titers of 1:28 and 1:26 after booster immunization, respectively (p<0.001). After long-term immunization, the neutralizing antibody titers of the two candidate vaccine groups increased, with average titers of 1:33 and 1:29, respectively.

[0096] 2. mRNA vaccine candidates induced higher levels of IFN-γ and IL-4

[0097] Helper T cell (Th) lymphocytes and cytokines play an important role in immune response, and Th1 / Th2 cells can reflect the balance and response of specific antiviral immunity. In order to evaluate the Th1 / Th2 situation at the single cell level, we used ELISpot to detect the levels of IFN-γ and IL-4 after booster immunization. After the first booster immunization, both DNA and mRNA candidate groups showed different IFN-γ and IL-4 immune spots under peptide pool stimulation ( Figure 5 A). After analyzing these spots, we observed that the mRNA vaccine candidate group secreted higher levels of IFN-γ and IL-4 ( Figure 5 B). Comparing the number of immunospots stimulated by different peptides, we found that the 16 / 18 / 20 peptide pool stimulated more cytokines than the 9 or 15 peptide pools. We also evaluated the number of IFNγ and IL-4 spots stimulated by single peptides and determined that the 16, 18, and 20 peptides indeed induced more IFN-γ and IL-4 production ( Figure 5 C).

[0098] After long-acting booster immunization, the production of IFN-γ and IL-4 was also detected, and the spots were larger than those of the first booster immunization ( Figure 5 D). Under the stimulation of 16 / 18 / 20 peptide pool, the levels of IFN-γ and IL-4 were still high, and the levels of spots exceeded those of the first booster immunization ( Figure 5 E). Single peptide analysis showed that peptides 16, 18, and 20 enhanced the secretion of IFN-γ and IL-4 ( Figure 5 F).

[0099] 3. Vaccine candidates enhance T cell responses

[0100] To further evaluate the T cell responses in immunized mice, we examined the CD4 + and CD8 + The secretion of IL-2, IL-4 and IFN-γ in T cells. Figure 6 A is an example showing the identification of CD4 + and CD8 + Experimental design and gating strategy for IFN-γ secretion in T cells were also used for the detection of IL-2 and IL-4. After the first booster immunization, CD4 + and CD8 + The secretion of IL-2, IL-4, and IFN-γ in T cells was significantly increased, while no significant difference was observed between the DNA group and the mRNA group ( Figure 6 B) After long-term immunization, CD4 + and CD8 + The secretion of IL-2, IL-4, and IFN-γ in T cells increased to varying degrees. + and CD8 + T cells induced more IL-2 and IL-4 secretion ( Figure 6 C).

[0101] Effector memory T cells (TEM) have the characteristics of homing ability, memory and persistence, which are essential for long-term immune protection. + and CD8 + Levels of Tem in T cells. CD4 + Gating strategy for Tem in T cells Figure 6 D, which is also used to detect CD8 + After the first booster immunization, MARV-specific CD4 + and CD8 + The number of TEM cells increased significantly, and the TEM level in the mRNA group was higher than that in the DNA group ( Figure 6 E) It is worth noting that after long-term immunization, the CD4 + Tem cells increased, while CD8 + There was no significant difference in Tem ( Figure 6 F).

[0102] 4. Immune response pathways activated by candidate vaccines

[0103] To explore the molecular mechanism of the candidate vaccine, we performed RNA-seq and transcriptome analysis on the spleen cells of immunized mice under peptide stimulation. The results showed that the candidate vaccine had an effect on the expression of a large number of genes, especially under the stimulation of 15 peptides. KEGG enrichment analysis was performed based on the upregulated genes. Compared with 9-peptide or 15-peptide, stimulation with 16 / 18 / 20 peptides significantly activated more immune response pathways. Compared with the control group, both candidate vaccine groups activated the B cell receptor signaling pathway, enhanced Th1 / 2 cell differentiation, and showed more interactions between viral proteins, cytokines, and cytokine receptors. In addition, GO enrichment analysis showed that both candidate vaccine groups activated pathways related to immune and inflammatory responses, T cell responses and humoral immunity, cytokines and cytokine receptors, and immune cell chemotaxis.

[0104] 5. Preliminary safety assessment of candidate vaccines

[0105] After long-term immunization, we collected the main organs of the mice and performed H&E staining ( Figure 7 A). No pathological changes were observed in any of the candidate vaccine groups. In addition, there were no significant differences among the three groups, which indicates the safety of the candidate vaccine. The behavior of the animals was also evaluated by an automated analysis system. Figure 7 B shows a representative heat map of the three groups of mice. By comparing the data of the three groups of mice, we found that there were no significant differences in the mice's activity time, distance, diet, grooming, and climbing ( Figure 7 C).

[0106] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0107] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A gene encoding Marburg virus glycoprotein, characterized in that The nucleotide sequence of the gene is shown in SEQ ID NO.

1.

2. A vector containing the gene according to claim 1.

3. The carrier according to claim 2, characterized in that The vector is a pVAX1 vector.

4. Use of the vector according to any one of claims 2 to 3 in the preparation of a DNA vaccine for preventing Marburg virus.

5. A DNA vaccine for preventing Marburg virus, characterized in that: Containing the carrier according to any one of claims 2 to 3.

6. An mRNA molecule expressing Marburg virus glycoprotein, characterized in that: The transcription template DNA of the mRNA molecule comprises the gene encoding the Marburg virus glycoprotein according to claim 1, and the transcription template DNA sequence is shown in SEQ ID NO.2; The mRNA molecule comprises a modified nucleoside, which is a pseudouridine.

7. The mRNA molecule expressing Marburg virus glycoprotein according to claim 6, characterized in that: The pseudouridine is N1-methyl-pseudouridine-5′-triphosphate, and all uridines in the mRNA molecule are replaced by N1-methyl-pseudouridine-5′-triphosphate.

8. Use of the mRNA molecule expressing Marburg virus glycoprotein according to any one of claims 6 to 7 in the preparation of an mRNA vaccine for preventing Marburg virus.

9. An mRNA vaccine for preventing Marburg virus, characterized in that: A method comprising the mRNA molecule expressing Marburg virus glycoprotein according to any one of claims 6 to 7.

Citation Information

Cited By

  • Marburg GP protein mutant, DNA molecule, recombinant vector and application thereof

    CN121494944A

  • Marburg gp protein mutant, dna molecule, recombinant vector and use thereof

    CN121494944B